DailyIQ
DailyIQ
Last updatedUpdating…

ILMN·Illumina, Inc.

$193.11
-7.70 (-3.84%)
After Hours
High
$200.00
Open
$197.57
Market Cap
29.15B
52W High
$309.35
Low
$191.25
P. Close
$193.11
P/E
32.57
52W Low
$112.65
Fwd P/E
31.19
DailyIQ Est.
$266.88
Inst. Own.
93.2%
Short Interest
5.31%
Days to Cover
3.7
NewEarnings release, scored · filed Oct 29, 2026tone -6.1 vs prior release · 42 lines scoredSee the breakdown
Technical Score (1D)
98
BULLISH
News Sentiment
53
MIXED
On Nov 20, Illumina announced that its BioInsight AI Lab had won the 2026 Virtual Cell Challenge using the CellularAI platform, a competition that highlighted the platform’s ability to predict cellular behavior from large biological datasets. The victory, reported on the same day, underscored the potential of CellularAI to accelerate drug discovery and biomedical research workflows and demonstrated Illumina’s integration of artificial intelligence with its core sequencing and array technologies. Earlier on Nov 20, the company also disclosed voluntary Class II recalls of several sequencing instruments due to cybersecurity vulnerabilities, a move that raised concerns about operational risk and data integrity. The recalls were reported to have coincided with a decline in the company’s share price, with a one‑day drop of 4.45 % and a 30‑day decline of 25.11 %. On Nov 19, a separate report noted that Illumina’s win in the Virtual Cell Challenge was powered by its Billion Cell Atlas data and a new CellularAI algorithm that accurately predicted cellular responses to genetic perturbations in unseen cell types, reinforcing the company’s leadership in large‑scale data and AI innovation. The Nov 20 article also compared Illumina to Royalty Pharma for value investors, noting that Royalty Pharma held a higher Zacks Rank and more favorable earnings and valuation metrics, while Illumina’s lower ranking and weaker analyst outlook made it less attractive for value-focused portfolios.
LOW TARGET
$165 -14.4%
2 analysts
MEAN TARGET
$261 +35.6%
16 analysts
HIGH TARGET
$365 +89.3%
10 analysts
PRICE RANGE
$165.00 - $365.00
SB / B / H / S / SS
6/9/10/2/1
DAILYIQ EST.
$266.88 (+38.4%)
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NMS
Country
United States
Symbol
ILMN
Description
Illumina is a global leader in genetic and genomic analysis, providing comprehensive sequencing and array-based solutions for a diverse customer base. The company's core offering includes instruments, consumables like reagents and flow cells, and various kits designed for whole-genome sequencing, targeted resequencing, and other applications. These products are utilized by a wide range of organizations, including research centers, academic institutions, and healthcare providers, to advance genomic research and diagnostics. Illumina's value proposition lies in its ability to offer cutting-edge tools and services that enable in-depth genetic analysis, contributing to advancements in fields like personalized medicine and disease research. The company distributes its products directly and through distributors, serving customers across the Americas, Europe, Asia Pacific, and other regions.
Bought (1Y)
0 shares
$0
Sold (1Y)
3,632,039 shares
$720.9M
Meister Keith A.-
Sell1,843 shares2026-11-11
Meister Keith A.-
Sell4,618 shares2026-11-11
Meister Keith A.-
Sell12,305 shares2026-11-11
Meister Keith A.-
Sell23,064 shares2026-11-11
Meister Keith A.-
Sell8,613 shares2026-11-11
76/ 100
Bullish
Overall: Bullish
✕Revenue declining year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
66.1%
Net Margin
19.6%
Revenue CAGR
15.6%
Current Ratio
2.08x
Debt / Equity
0.43x
Return on Equity
31.2%
Earnings Summary
In the most recent quarters, Illumina demonstrated consistent earnings growth. Q1 2026 EPS of $1.15 surpassed the $1.05477 estimate, while Q2 2026 EPS of $1.31 beat the $1.22632 forecast, reflecting a steady acceleration in profitability. Revenue, however, showed a mixed trajectory: Q1 2026 revenue of $1.091B exceeded the $1.07319B estimate, yet Q3 2026 revenue fell to $1.129B against a $1.17721B estimate, indicating a slight deceleration in top-line growth. Across the last four quarters, the company has beaten earnings estimates in three instances, maintaining a strong earnings beat pattern. Historically, Illumina has posted year-over-year revenue growth, with a notable 76.2% year-to-date return in 2026 driven by NovaSeq X adoption and expanding clinical sequencing demand. The company has consistently outperformed analyst expectations on EPS, even when revenue growth has moderated, highlighting a resilient profitability profile. This pattern of strong earnings beats amid fluctuating revenue underscores Illumina’s ability to manage cost structures and maintain margins. Recent news highlights a November 11 announcement of a 76.2% YTD return and a new duplex sequencing workflow for ultra-sensitive circulating tumor DNA monitoring, reinforcing the company’s clinical consumables strategy. Insider selling by director Keith A. Meister on November 9 may signal short-term confidence concerns, though it does not appear to have materially impacted the company’s earnings trajectory. Key will be the company’s ability to sustain its earnings beat momentum while navigating the mixed revenue environment.

EPS

EstBeatMiss
$0.85$1.05$1.25$1.45$1.65Q1'25Q1'26Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$1.56 - -
Q3'26$1.38$1.44+4.1%
Q2'26$1.23$1.31+6.8%
Q1'26$1.05$1.15+9.0%
Q1'25$0.94$0.97+3.3%

Revenue

EstBeatMiss
$1.0B$1.1B$1.1B$1.2B$1.3BQ1'25Q1'26Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$1.3B - -
Q3'26$1.2B$1.1B-4.1%
Q2'26$1.2B$1.2B+0.6%
Q1'26$1.1B$1.1B+1.7%
Q1'25 - $1.0B -

Market Data

ILMN Stock Snapshot

BULLISH98/100
$193.00−$0.11 (0.1%)
Market cap
29.15B
P/E ratio
32.6
Day range
$191.25 – $200.00
News sentiment
53/100 · Neutral
Analyst target
$261.45 (+35.5%)
Consensus
Hold · 28 analysts
52-week range+71.3% off low · -37.6% from high
$112.65$309.35
Price $193.00 DailyIQ Est. $266.88

Momentum is working in ILMN's favour - it ranks in the upper part of DailyIQ's momentum universe. In Healthcare, names this size usually take direction from sector flows before company-level news.

Behaviour On Record

What ILMN's own history says about today's numbers

Realized volatility (21d)
73.3% 95th pct
Below its peak
-62.2%
vs 200-day average
+6.8%
Up days (1y)
52%

Illumina, Inc. is currently running 73.3% annualised volatility over the last 21 sessions. Measured against ILMN's own 13 years of daily returns rather than a market-wide average, that is the 95th percentile — an extreme by its own standards, against a typical reading of 36.9%.

ILMN is trading -62.2% below its running peak. Across 13 full years on file, its median worst-drawdown-in-a-year was -34.4%, and the deepest was -60.1% in 2023. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began, and where past declines also continued.

Price sits +6.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 56th percentile — a somewhat wider gap than its own norm. Over the past year ILMN closed higher on 52% of sessions, and it is currently 2 sessions into a falling streak.

On November specifically: over 13 years of records, ILMN finished the month higher 6 of 13 times, with a median return of -0.6% and an average of +2.1%. Its strongest month historically has been January at +4.5% on average, its weakest February at -3.4%.

Overnight risk is measurable too: ILMN has opened more than 2% away from the prior close in 171 of 3,267 sessions (5.2% of the time), with the largest gaps running +8.1% and -10.2%.

Across the last 3 dated reports on file, ILMN moved an average of 3.2% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.5% and a largest of -8.3%.

All figures computed from 3,268 daily closes between 2013-11-22 and 2026-11-20, split-adjusted, recomputed daily. Percentiles are against ILMN's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ILMN's sector?

Illumina, Inc. sits in the Health Care sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#5 of 12
Sector state
Leading
Sector rotation score
82

Options Market

What is the options market pricing for ILMN?

CallsPuts

For Illumina, Inc.'s nearest expiry (2026-12-18, 26 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.68), with at-the-money implied volatility around 63.1%. The options market is pricing roughly a ±16.2% move by that expiry — a range of about $176.55–$244.96.

Put/call ratio (2026-12-18)
0.68
ATM implied volatility
63.1%
Total open interest
4,234
Expected move by 2026-12-18
±16.2% ($176.55–$244.96)

Analyst Rating Changes

Are analysts turning bullish or bearish on ILMN?

Citigroup most recently reiterated its rating on Illumina, Inc. to Sell on Nov 2, 2026 with a price target of $210 (from $113). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
Citigroup: Sell
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Nov 2, 2026CitigroupMaintainedSell$113 → $210
Oct 30, 2026JP MorganMaintainedOverweight$320 → $300
Oct 30, 2026Evercore ISI GroupMaintainedOutperform$290 → $275
Oct 19, 2026Canaccord GenuityMaintainedHold$205 → $300
Oct 13, 2026TD CowenMaintainedHold$210 → $270
Oct 7, 2026BarclaysMaintainedUnderweight$160 → $200
Oct 5, 2026RBC CapitalMaintainedOutperform$230 → $310
Oct 1, 2026GuggenheimMaintainedBuy$226 → $305
Sep 29, 2026Leerink PartnersMaintainedOutperform$220 → $300
Sep 28, 2026Piper SandlerMaintainedOverweight$225 → $305
Sep 9, 2026UBSUpgradeNeutral → Buy$135 → $260
Sep 3, 2026Argus ResearchMaintainedBuy$180 → $235

Earnings Release, Scored

What did Illumina, Inc.'s latest earnings release say?

Filed Oct 29, 2026 · SEC Form 8-K, Exhibit 99

Tone60.8/ 100-6.1 vs prior release
Hedging words0.63per 100 words+0.63 vs prior release
Tone, last 3 releasesScale 50–76

Most important lines

  1. 1

    (b) Excludes the impacts of International Emergency Economic Powers Act (IEEPA) tariff refunds expected to be recovered, consisting primarily of a $79 million benefit recognized as a reduction to cost of revenue in Q3 2026 and a reduction to revenue of $37 million for the portion of tariff refunds that we expect to credit to customers.

    New this quarter
  2. 2

    Organic revenue growth greater than 4% and ROW organic revenue growth greater than 5%, both unchanged versus prior guidance.

    New this quarter
  3. 3

    Revenue excluding tariff refunds was $1.17 billion, up 4.7% after also excluding the impacts of currency, acquisitions, and the Greater China region (“ROW 1 organic revenue growth”).

    New this quarter

Peers & ETF holders

ILMN peers & ETF holders

News & sentiment

What is the news saying about ILMN?

ILMN fell 28.0% over the month to Nov 20. News tone held between 0 and 73 from Oct 20 to Nov 5, then jumped to 65 on Nov 9.

Daily close and news tone, Oct 20 to Nov 20
$200$250$300Oct 20: tone 40Oct 21: tone 61Oct 22: tone 54Oct 23: tone 58Oct 26: tone 50Oct 27: tone 52Oct 28: tone 73Oct 29: tone 56Oct 30: tone 51Nov 2: tone 54Nov 3: tone 66Nov 4: tone 39Nov 5: tone 0Nov 6Nov 9: tone 65Nov 10: tone 68Nov 11: tone 68Nov 12: tone 44Nov 13: tone 57Nov 16Nov 17: tone 70Nov 18: tone 61Nov 19: tone 25Nov 20: tone 58Oct 20News toneNov 20123
  1. Oct 29 -10.7%same day: Sequencer as a Service Global Market Report 2026 | Capitalize on 20% CAGR to $5.73 Billion by 2030 as Illumina, BGI Genomics, Eurofins and Novogene Scale AI and Cloud Genomics
  2. Oct 30 -8.3%same day: Illumina Crashes As Tariffs, AI Woes Eat Into 157% Run-Up
  3. Nov 5 -9.7%
Latest stories naming Illumina

Technical analysis

How strong is ILMN's momentum right now?

On the daily chart ILMN ranks at the 98th percentile for momentum against 1,063 stocks and ETFs, a bullish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling ILMN?

110 of the 207 tracked managers added to ILMN in their latest 13F and 94 trimmed. Together they own 93.2% of the company, worth $38.5B. Fidelity and BlackRock alone hold 21.2%.

110adding94trimming3unchanged
Largest holders by stake, latest 13FBar = share of ILMN
  1. $4.4B positionAdded 257.8% last quarter
  2. $4.3B positionTrimmed 17.4% last quarter
  3. $2.7B positionAdded 50.1% last quarter
  4. $2.7B positionTrimmed 35.9% last quarter
  5. $2.0B positionAdded 10.5% last quarter
  6. $1.7B positionTrimmed 4.3% last quarter
  7. $1.6B positionTrimmed 7.6% last quarter
  8. $1.3B positionAdded 318.4% last quarter
  9. $1.2B positionAdded 43.2% last quarter
  10. $955.4M positionTrimmed 0.7% last quarter
Full holdings history

Congressional trading

Is Congress trading ILMN?

4 members of Congress disclosed 8 ILMN trades between Dec 28, 2018 and Oct 27, 2026: 4 buys and 4 sells, about $64.0K in estimated value.

BuysSells2020202220242026
BuySell$1K–$15K$15K–$50K$50K–$100K$100K–$250K

What stands out

Click one to highlight its trades in the chart

Discover more

How has ILMN done against its peers?

Over the six months to Nov 20, ILMN returned +35.6%. Of the 15 related stocks and ETFs, 8 did better, led by CRL at +101.4%.

Change since May 20, through Nov 20
−50%0%+50%+100%+150%May 20JulAugSepOctNovNov 20CRL +101.4%ILMN +35.6%XLV +20.5%